Autoimmune Stack

Thymosin alpha-1 + KPV + BPC-157 + GLP-1 (LDN in creator variants — not a peptide) — RA/joint autoimmune inflammation — Jones DC.

⚠ Safety first — read this before anything else on this page

Approval status: No stack is FDA-approved, and this combination has never been tested in humans. Thymosin alpha-1 is an approved drug in 35+ other countries as Zadaxin — it is not FDA-approved in the US, and the FDA's advisory committee voted 17–4 against adding it to the compounding list in December 2024.

What has actually happened to people:

This stack aims at the immune system in people who have immune diseases — precisely where unsupervised experimentation carries the most risk. An immune-modulating experiment layered on an autoimmune condition, or on the medicines treating it, has never been studied in any combination.
The GLP-1 layer carries its own documented record: the FDA's July 2024 alert on compounded-vial measurement errors and hospitalizations applies to anyone drawing this class from a vial (see our compounded GLP-1 page in Dangers).

What nobody knows: No interaction data exists between any pair in this stack, let alone all four — and none exists between these compounds and standard autoimmune medications. That matrix is the risk.

Get medical care now if:

A flare of your underlying condition, new joint swelling, fever, or signs of infection — immune suppression and stimulation both hide here; see your own specialist promptly and disclose everything you are taking.
Severe or persistent vomiting, or signs of dehydration, on the GLP-1 layer — seek care.
Swelling of the lips or tongue, or trouble breathing, after any injection — call emergency services.

Who should stay away: Anyone with an autoimmune condition who has not told their treating specialist — non-disclosure is how interactions hurt people. Anyone on immunosuppressant medication. Minors and anyone pregnant.

The product problem: A four-layer stack multiplies the identity problem: every component has to be what its label says. Across all compounds, independent tester Finnrick Analytics finds roughly one in three gray-market samples failing basic expectations (February 2026).

Talk to a doctor who knows you are taking it. See our doctors directory. If you were harmed, report it to FDA MedWatch — your report is how the record gets built.

We don't publish doses, protocols, or sources — for any compound, ever. Our Legal Mandate.

Components: Thymosin alpha-1 + KPV + BPC-157 + GLP-1 (LDN in creator variants — not a peptide)

What creators claim: RA/joint autoimmune inflammation — Jones DC.

Evidence note: All creator-claim layer; immune conditions are precisely where unsupervised experimentation carries the most risk.

Stub page — full treatment after the transcript bank is mined for this stack. No stack on this site carries instructions of any kind.

Educational information only — not medical or legal advice. Status as of November 7, 2026. See Our Legal Mandate.

Autoimmune Stack

Educational information only

Before you act on anything here

THE NETWORK — ONE PUBLISHER, EVERY FRONT